Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Chabner

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Clinical Advances in Hematology & Oncology : H&O|March 7, 2008
Advances and challenges in the use of biomarkers in clinical trialsBruce Chabner
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2007
Phase II cancer trials: out of control?Bruce Chabner
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Approval of New Agents after Phase II TrialsBruce Chabner
The Oncologist|November 25, 2004
"The patient failed chemotherapy" ...an expunged phraseKaren Parles, Bruce Chabner
The New England Journal of Medicine|July 30, 2015
Structural Approaches to Cancer Drug DevelopmentBruce Chabner, Victoria Richon
Lancet (London, England)|June 5, 2003
Using "rationally designed drugs" rationallyJim Brugarolas, Jeffrey W Clark, Bruce Chabner
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Targeted agents: the rules of combinationEunice L Kwak, Jeffrey W Clark, Bruce Chabner
The Oncologist|July 26, 2017
The Harm in KratomJoshua Z Drago, Bennett Lane, Jonathan Kochav, et al.
Targeted Oncology|November 9, 2017
Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest DevelopmentsAiko Nagayama, Leif W Ellisen, Bruce Chabner, et al.
The Oncologist|May 20, 2015
Recognizing the Financial Burden of Cancer Patients in Clinical TrialsRyan D Nipp, Elizabeth Powell, Bruce Chabner, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Clinical Advances in Hematology & Oncology : H&O|March 7, 2008
Advances and challenges in the use of biomarkers in clinical trialsBruce Chabner
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2007
Phase II cancer trials: out of control?Bruce Chabner
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Approval of New Agents after Phase II TrialsBruce Chabner
The Oncologist|November 25, 2004
"The patient failed chemotherapy" ...an expunged phraseKaren Parles, Bruce Chabner
The New England Journal of Medicine|July 30, 2015
Structural Approaches to Cancer Drug DevelopmentBruce Chabner, Victoria Richon
Lancet (London, England)|June 5, 2003
Using "rationally designed drugs" rationallyJim Brugarolas, Jeffrey W Clark, Bruce Chabner
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Targeted agents: the rules of combinationEunice L Kwak, Jeffrey W Clark, Bruce Chabner
The Oncologist|July 26, 2017
The Harm in KratomJoshua Z Drago, Bennett Lane, Jonathan Kochav, et al.
Targeted Oncology|November 9, 2017
Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest DevelopmentsAiko Nagayama, Leif W Ellisen, Bruce Chabner, et al.
The Oncologist|May 20, 2015
Recognizing the Financial Burden of Cancer Patients in Clinical TrialsRyan D Nipp, Elizabeth Powell, Bruce Chabner, et al.
Pageof 2